Search Results

The executive spoke with Biospace about Codagenix’s nasal COVID-19 spray vaccine, the COVID market, and how the company fits into the broader infectious disease space.

Codagenix Inc. announced that the BARDA has entered into a contract with Codagenix to support the costs of a Phase 2b clinical study of CoviLiv™ for the prevention of symptomatic COVID-19 in people who have completed their primary approved/authorized COVID-19 vaccine series and their last COVID-19 vaccine was at least 3 months beforehand.

Codagenix Inc. today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer.

Codagenix Inc. today announced that the US Department of Defense (DoD), through the US Army Medical Research and Development Command and the US Army Medical Research Acquisition Activity, has awarded the Company $5.88 million to advance the development of its CodaVax-DENV, a tetravalent live attenuated dengue vaccine program.

Codagenix Inc. announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.

Codagenix Inc. today announced the presentation of preclinical data for CodaLytic™, a codon-modified virus being developed for breast cancer immunovirotherapy, at the Society for the Immunotherapy of Cancer (SITC) 38th Annual Meeting being held virtually and in-person November 1-5, 2023 in San Diego, California.

Codagenix Inc. today announced the completion of a $25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital.